Stephen E. Gitelman

Pediatric Endocrinology
1500 Owens St Ste 300
San Francisco, CA 94158

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications

Type 1 Diabetes Driven by Residual Recipient T Cells After Hematopoietic Cell Transplantation: A Case Report.

Type 1 Diabetes Driven by Residual Recipient T Cells After Hematopoietic Cell Transplantation: A Case Report.

Journal: Diabetes care
Published: April 09, 2026

How to communicate with individuals and caregivers at the time of presymptomatic type 1 diabetes diagnosis.

How to communicate with individuals and caregivers at the time of presymptomatic type 1 diabetes diagnosis.

Journal: Postgraduate medicine
Published: February 25, 2026

Type 1 diabetes screening: reframing the debate from paternalism to partnership. Reply to Scaramuzza AE, Iafusco D, Cherubini V [letter] Type 1 diabetes screening: building a clinician-patient partnership for early care of chronic beta cell failure. Reply to Mallone R, Bandini A [letter].

Type 1 diabetes screening: reframing the debate from paternalism to partnership. Reply to Scaramuzza AE, Iafusco D, Cherubini V [letter] Type 1 diabetes screening: building a clinician-patient partnership for early care of chronic beta cell failure. Reply to Mallone R, Bandini A [letter].

Journal: Diabetologia
Published: December 18, 2025

Real-world experience with teplizumab in stage 2 type 1 diabetes: a plain language summary.

Real-world experience with teplizumab in stage 2 type 1 diabetes: a plain language summary.

Journal: Therapeutic advances in endocrinology and metabolism
Published: November 24, 2025

Glucocorticoids to Manage Cytokine Release Syndrome During Teplizumab Therapy for New-Onset Type 1 Diabetes.

Glucocorticoids to Manage Cytokine Release Syndrome During Teplizumab Therapy for New-Onset Type 1 Diabetes.

Journal: Diabetes care
Published: October 10, 2025

Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes.

Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes.

Journal: Diabetologia
Published: September 08, 2025

Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes.

Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes.

Journal: Diabetes
Published: August 19, 2025

Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset.

Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset.

Journal: Diabetologia
Published: April 15, 2025

Exploring Microbiota-Associated Metabolites in Twins Discordant for Type 1 Diabetes.

Exploring Microbiota-Associated Metabolites in Twins Discordant for Type 1 Diabetes.

Journal: medRxiv : the preprint server for health sciences
Published: March 04, 2025

Serum Metabolomics Reveals Potential Differences in Gut Microbiota-Associated Metabolites in Twins Discordant for Type 1 Diabetes.

Serum Metabolomics Reveals Potential Differences in Gut Microbiota-Associated Metabolites in Twins Discordant for Type 1 Diabetes.

Journal: Diabetes
Published: February 14, 2025

Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes.

Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes.

Journal: Diabetes, obesity & metabolism
Published: November 27, 2024

A microRNA-based dynamic risk score for type 1 diabetes.

A microRNA-based dynamic risk score for type 1 diabetes.

Journal: Nature medicine
Published: September 08, 2024
Showing 1-12 of 76

Last Updated: 09/26/2026